Review Article
Volume 4 Issue 2 - 2021
Benign Prostatic Hyperplasia (BPH): Perennial Plague of the Prostate
Nicholas A Kerna1,2*, Uzoamaka Nwokorie3, John V Flores4,5, Hilary M Holets4,5, Lawrence U Akabike6, Mark H Chen7, Emmaneulla Olubumni Solomon8, Kevin D Pruitt9 and Shain Waugh10
1SMC–Medical Research, Thailand
2First InterHealth Group, Thailand
3University of Washington, USA
4Beverly Hills Wellness Surgical Institute, USA
5Orange Partners Surgicenter, USA
6Larrico Enterprises, LLC, USA
7For Your Health, LLC, USA
8Obafemi Awolowo University, Nigeria
9Kemet Medical Consultants, USA
*Corresponding Author: Nicholas A Kerna, (mailing address) POB47 Phatphong, Suriwongse Road, Bangkok, Thailand 10500.
Received: December 28, 2020; Published: January 30, 2021




Abstract

Benign prostatic hyperplasia (BPH) is a common condition with lower urinary tract symptoms (LUTS) in middle-aged and older men. BPH is the most prevalent non-malignant urological disorder. Nearly three hundred years ago, an enlarged prostate was recognized to cause urinary retention. LUTS include inconsistent urine flow, partial or complete urine retention, increased urinary frequency, difficulty emptying the bladder, nocturia, and dysuria. BPH is not a life-threatening condition; however, increased severity can cause urinary tract infections, bleeding, bladder stones, and kidney damage. BPH diagnosis is made by symptom score, quality-oflife (QoL) score, physical examination, and diagnostic imaging, such as ultrasonography, cystoscopy, and uroflowmetry. Age, genetics, and other factors, including lifestyle, affect BPH development and progression. Conservative treatment for BPH includes watchful waiting, pharmacological intervention, and specific lifestyle changes. There are a variety of surgical interventions available, the choice of which is based upon several factors. However, surgical intervention is a last resort for BPH treatment and is used primarily refractory from medications or in severe symptoms and complications. Invasive techniques include minimally invasive therapy and novel treatment modalities, as described in this paper.

Keywords: Ablation; Prostate Enlargement; Saw Palmetto; Urinary Tract Infection; Watchful Waiting

References

  1. CG Roehrborn. “Pathology of benign prostatic hyperplasia”. International Journal of Impotence Research 3 (2008): 11-18. https://pubmed.ncbi.nlm.nih.gov/19002119/
  2. JN Hellwege., et al. “Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network”. Scientific Reports 1 (2019): 1-10. https://pubmed.ncbi.nlm.nih.gov/30988330/
  3. B Fibbi., et al. “Chronic inflammation in the pathogenesis of benign prostatic hyperplasia”. International Journal of Andrology 3 (2010): 475-488. https://pubmed.ncbi.nlm.nih.gov/19508330/
  4. JK Parsons. “Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors”. Current Bladder Dysfunction Reports 4 (2010): 212-218. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061630/
  5. M Altok., et al. “Chromosomal aberrations in benign prostatic hyperplasia patients”. Korean Journal of Urology 571 (2016): 45-49. https://pubmed.ncbi.nlm.nih.gov/26966725/
  6. G Untergasser., et al. “Benign prostatic hyperplasia: Age-related tissue-remodeling”. Experimental Gerontology 3 (2005): 121-128. https://www.researchgate.net/publication/7971845_Benign_prostatic_hyperplasia_Age-related_tissue-remodeling
  7. M Hennenberg., et al. “Cooperative effects of EGF, FGF, and TGF-β1 in prostate stromal cells are different from responses to single growth factors”. Life Sciences 123 (2015): 18-24. https://pubmed.ncbi.nlm.nih.gov/25529149/
  8. S Wen., et al. “Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer”. American Journal of Pathology 2 (2015): 293-301. https://pubmed.ncbi.nlm.nih.gov/25432062/
  9. TM Nicholson and WA Ricke. “Androgens and estrogens in benign prostatic hyperplasia: Past, present and future”. Differentiation4-5 (2011): 184-199. https://pubmed.ncbi.nlm.nih.gov/21620560/
  10. X Shi., et al. “Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells”. Prostate 14 (2017): 1424-1437. https://pubmed.ncbi.nlm.nih.gov/28850686/
  11. P Alonso-Magdalena., et al. “A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia”. Proceedings of the National Academy of Sciences of the United States of America8 (2009): 2859-2863. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650376/
  12. Y Bostanci., et al. “Correlation between benign prostatic hyperplasia and inflammation”. Current Opinion in Urology 1 (2013): 5-10. https://pubmed.ncbi.nlm.nih.gov/23159991/
  13. G Gandaglia., et al. “The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH)”. BJU International4 (2013): 432-441. https://pubmed.ncbi.nlm.nih.gov/23650937/
  14. D Parikesit., et al. “The impact of obesity towards prostate diseases”. Prostate International1 (2016): 1-6. https://www.sciencedirect.com/science/article/pii/S228788821530074X
  15. GW Cannon., et al. “A Preliminary Study of JM-27: A Serum Marker That Can Specifically Identify Men With Symptomatic Benign Prostatic Hyperplasia”. Journal of Urology2 (2007): 610-614. https://pubmed.ncbi.nlm.nih.gov/17222644/
  16. SD Lokeshwar., et al. “Epidemiology and treatment modalities for the management of benign prostatic hyperplasia”. Translational Andrology and Urology 5 (2019): 529-539. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842780/
  17. MS Choo., et al. “Alcohol, smoking, physical activity, protein, and lower urinary tract symptoms: Prospective longitudinal cohort”. International Neurourology Journal 3 (2015): 197-206. https://pubmed.ncbi.nlm.nih.gov/26620903/
  18. CL Lee and HC Kuo. “Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts”. Tzu Chi Medical Journal2 (2017): 79-83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509197/
  19. G Bartsch., et al. “Consensus statement: The role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia”. BJU International1 (2004): 27-29. https://pubmed.ncbi.nlm.nih.gov/15009083/
  20. US Shah., et al. “Androgen regulation of JM-27 is associated with the diseased prostate”. Journal of Urology4 (2006): 1437. https://pubmed.ncbi.nlm.nih.gov/15223850/
  21. GC Luo., et al. “Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction”. Singapore Medical Journal9 (2013): 482-486. https://pubmed.ncbi.nlm.nih.gov/24068054/
  22. , et al. “Singapore urological association clinical guidelines for male lower urinary tract symptoms/benign prostatic hyperplasia”. Singapore Medical Journal 58.8 (2017): 473-480. https://pubmed.ncbi.nlm.nih.gov/28848988/
  23. H Lepor. “Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia”. Urologic Clinics of North America3 (2016): 311-323. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213889/
  24. JH Jung., et al. “Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia”. Cochrane Database of Systematic Reviews 11 (2017). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486059/
  25. RS Rittmaster., et al. “for Atrophy Men Given Finasteride * of”. (1996): 814-819.
  26. V Mysore and BM Shashikumar. “Guidelines on the use of finasteride in androgenetic alopecia”. Indian Journal of Dermatology, Venereology and Leprology2 (2016): 128-134. https://pubmed.ncbi.nlm.nih.gov/26924401/
  27. RS Rittmaster. “5Α-Reductase Inhibitors in Benign Prostatic Hyperplasia and Prostate Cancer Risk Reduction”. Best Practice and Research: Clinical Endocrinology and Metabolism2 (2008): 389-402. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180399/
  28. JD McConnell., et al. “The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia”. New England Journal of Medicine25 (2003): 2387-2398. https://pubmed.ncbi.nlm.nih.gov/14681504/
  29. C Konstantinidis., et al. “Lower urinary tract symptoms associated with benign prostatic hyperplasia: Combined treatment with fesoterodine fumarate extended-release and tamsulosin - A prospective study”. Urologia Internationalis2 (2013):156-160. https://pubmed.ncbi.nlm.nih.gov/23221480/
  30. B S., et al. “Saw palmetto for benign prostatic hyperplasia”. Medical Letter on Drugs and Therapeutics”. The New England Journal of Medicine 1046 (1999): 18. https://pubmed.ncbi.nlm.nih.gov/16467543/
  31. MS Karadeniz., et al. “Bipolar versus monopolar resection of benign prostate hyperplasia: a comparison of plasma electrolytes, hemoglobin and TUR syndrome”. Springer Plus1 ( 2016). https://pubmed.ncbi.nlm.nih.gov/27777873/
  32. CE Méndez-Probst., et al. “A multicentre single-blind randomized controlled trial comparing bipolar and monopolar transurethral resection of the prostate”. Journal of the Canadian Urological Association6 (2011): 385-389. https://pubmed.ncbi.nlm.nih.gov/22154630/
  33. M Marszalek., et al. “Transurethral Resection of the Prostate”. European Urology, Supplements6 (2009): 504-512. https://www.mayoclinic.org/tests-procedures/turp/about/pac-20384880
  34. PJ Gilling., et al. “The use of the holmium laser in the treatment of benign prostatic hyperplasia”. Journal of Endourology5 (1996): 459-461. https://pubmed.ncbi.nlm.nih.gov/8905494/
  35. A Srinivasan and R Wang. “An update on minimally invasive surgery for benign prostatic hyperplasia: Techniques, risks, and efficacy”. World Journal of Men’s Health4 (2019): 402-411. https://pubmed.ncbi.nlm.nih.gov/31496146/
  36. JM Kuebker and NL Miller. “Holmium Laser Enucleation of the Prostate: Patient Selection and Outcomes”. Current Urology Reports12 (2017). https://pubmed.ncbi.nlm.nih.gov/29046983/
  37. Y Zhu., et al. “Thulium laser versus standard transurethral resection of the prostate for benign prostatic obstruction: a systematic review and meta-analysis”. World Journal of Urology4 (2015): 509-515. https://pubmed.ncbi.nlm.nih.gov/25298242/
  38. AM Elshal., et al. “GreenLightTM laser (XPS) photoselective vapo-enucleation versus holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic hyperplasia: A randomized controlled study”. Journal of Urology3 (2015): 927-934. https://pubmed.ncbi.nlm.nih.gov/26206674/
  39. P Jones., et al. “UroLift: A new minimally-invasive treatment for benign prostatic hyperplasia”. Therapeutic Advances in Urology6 (2016): 372-376. https://pubmed.ncbi.nlm.nih.gov/27904652/
  40. N Shore., et al. “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia”. Therapeutic Advances in Urology 11 (2019): 175628721882080. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348527/
  41. U Teichgräber., et al. “Prostate Artery Embolization: Indication, Technique and Clinical Results”. RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren (2018). https://pubmed.ncbi.nlm.nih.gov/29975976/
  42. J Westwood., et al. “Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia”. Therapeutic Advances in Urology11 (2018): 327-333. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/
  43. S Taktak., et al. “Aquablation: a novel and minimally invasive surgery for benign prostate enlargement”. Therapeutic Advances in Urology6 (2018): 183-188. https://journals.sagepub.com/doi/full/10.1177/1756287218760518
Citation: Kerna NA, Nwokorie U, Flores JV, Holets HM, Akabike LU, Chen MH, Solomon EO, Pruitt KD, Waugh S. “Benign Prostatic Hyperplasia (BPH): Perennial Plague of the Prostate”. EC Clinical and Medical Case Reports 4.2 (2021): 53-61.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk